Cardiff Oncology Inc - Asset Resilience Ratio
Cardiff Oncology Inc (CRDF) has an Asset Resilience Ratio of 65.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Cardiff Oncology Inc's Asset Resilience Ratio has changed over time. Check Cardiff Oncology Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cardiff Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Cardiff Oncology Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.83 Million | 65.98% |
| Total Liquid Assets | $40.83 Million | 65.98% |
Asset Resilience Insights
- Very High Liquidity: Cardiff Oncology Inc maintains exceptional liquid asset reserves at 65.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cardiff Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Cardiff Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Cardiff Oncology Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Cardiff Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.98% | $40.83 Million | $61.88 Million | +24.54pp |
| 2024-12-31 | 41.44% | $40.28 Million | $97.19 Million | -23.69pp |
| 2023-12-31 | 65.13% | $53.17 Million | $81.64 Million | -11.40pp |
| 2022-12-31 | 76.53% | $88.92 Million | $116.19 Million | -9.65pp |
| 2021-12-31 | 86.18% | $128.88 Million | $149.54 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $134.73 Million | -- |
| 2016-12-31 | 54.56% | $23.98 Million | $43.95 Million | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more